Evidence map›Paper›PMID 25896683›Full record

ReviewJournal of neurology, neurosurgery, and psychiatry2016

Camptocormia in Parkinson's disease: definition, epidemiology, pathogenesis and treatment modalities.

Prachaya Srivanitchapoom, Mark Hallett

Registry-linked trialAbstract readReview
In one paragraph

Review in Journal of neurology, neurosurgery, and psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03573232 (Prevalence of Abnormal Postures in Parkinson's Disease), which is not on this map. Cited by 56 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 2 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03573232 unknown statusnot on this mapstarted 2018, after this paper: background citation

Prevalence of Abnormal Postures in Parkinson's Disease: an Observational Multicenter Study

TypeobservationalSponsorUniversita di VeronaRan2018 to 2018Enrolled794ConditionsParkinson Disease
3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 128 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Botulinum Neurotoxin Treatment of Camptocormia- A Critical Review and Update.Tremor and other hyperkinetic movements (New York, N.Y.) · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. The Sloping-Type Adult Spinal Deformity.Spine surgery and related research · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Prachaya SrivanitchapoomFaculty of Medicine, Division of Neurology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Mark HallettHuman Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
National Institute of Neurological Disorders and Stroke · US

Funding

Pathophysiology of Basal Ganglia DisordersZIANS003031 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI HALLETT, MARK · 2009 to 2023
$22.7M
Intramural NIH HHS ZIA NS003031
6 · The paper itself

Abstract

Camptocormia is an axial postural deformity characterised by abnormal thoracolumbar spinal flexion. The symptom usually presents while standing, walking or exercising and is alleviated while sitting, lying in a recumbent position, standing against a wall or using walking support. There is no consensus on the degree of thoracolumbar flexion to define camptocormia. However, most authors usually use an arbitrary number of at least 45° flexion of the thoracolumbar spine when the individual is standing or walking. Aetiologies of camptocormia are heterogeneous, and Parkinson's disease (PD) is one of its many causes. The prevalence of camptocormia in PD ranges from 3% to 18%. Central and peripheral mechanisms might both contribute to its pathogenesis. Although there is no established consensus for treatment of camptocormia in PD, there are non-pharmacological, pharmacological and surgical approaches that can be used.

Indexed as

Antiparkinson AgentsHumansMuscular Atrophy, SpinalParkinson DiseaseSpinal CurvaturesTerminology as TopicAntiparkinson AgentsCLINICAL NEUROLOGYMOVEMENT DISORDERSPARKINSON'S DISEASE

Identifiers

PMID25896683
PMCPMC5582594
OpenAlexW2071597984

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.